Exelixis, Inc. - Common Stock (NQ:EXEL)

58.92 +0.53 (+0.92%)

Delayed Quote Updated: 1:15 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

23 24 Next >

Don't overlook NASDAQ:EXEL—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

June 06, 2024

EXELIXIS INC (NASDAQ:EXEL) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

May 31, 2024

Via Benzinga

Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying ↗

May 31, 2024

Via Benzinga

Exelixis to Present at the William Blair 44th Annual Growth Stock Conference

May 28, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

May 20, 2024

From Exelixis, Inc.

Via Business Wire

The Analyst Verdict: Exelixis In The Eyes Of 5 Experts ↗

May 01, 2024

Via Benzinga

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

May 15, 2024

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

Via Chartmill

Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You? ↗

May 12, 2024

These stocks are both experts in their respective fields.

Via The Motley Fool

MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths' ↗

May 10, 2024

Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.

Via Benzinga

Just Say No to Drugs: 3 Pharma Stocks to Avoid ↗

May 08, 2024

Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios.

Via InvestorPlace

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

May 07, 2024

From Exelixis, Inc.

Via Business Wire

Technical Signals Point to a Possible Breakout for EXELIXIS INC. ↗

April 24, 2024

EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know.

Via Chartmill

What Analysts Are Saying About Exelixis Stock ↗

April 10, 2024

Via Benzinga

2 Stocks Under $30 to Buy and Hold ↗

February 19, 2024

You don't need to be a millionaire to get started. Investing on a budget can work, too.

Via The Motley Fool

Exelixis (EXEL) Q1 2024 Earnings Call Transcript ↗

May 01, 2024

EXEL earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

EXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024 ↗

April 30, 2024

EXEL stock results show that Exelixis missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

April 30, 2024

From Exelixis, Inc.

Via Business Wire

The Top 3 Biotech Stocks to Buy in April 2024 ↗

April 27, 2024

Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances.

Via InvestorPlace

NASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

April 24, 2024

EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.

Via Chartmill

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024

April 16, 2024

From Exelixis, Inc.

Via Business Wire

NASDAQ:EXEL is an undervalued gem with solid fundamentals. ↗

March 29, 2024

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

Via Chartmill

3 Biotech Stocks to Buy on the Dip: March 2024 ↗

March 27, 2024

Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.

Via InvestorPlace

4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗

March 23, 2024

Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.

Via The Motley Fool

Topics Stocks

5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 ↗

March 09, 2024

Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...

Via Talk Markets

2 Biotech Stocks to Buy Hand Over Fist in March ↗

March 08, 2024

These stocks are worth buying in most months of the year.

Via The Motley Fool

3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success ↗

March 06, 2024

With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.

Via InvestorPlace

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

March 05, 2024

EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗

March 02, 2024

The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.

Via The Motley Fool

Topics Stocks

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

February 27, 2024

From Exelixis, Inc.

Via Business Wire

Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying ↗

February 23, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.